April 25th, 2012
When You’re Hot, You’re Hot: Salim Yusuf Second Most Influential Scientist in 2011
Larry Husten, PHD
McMaster University’s Salim Yusuf has tied for second place in the annual ranking of the “hottest” scientific researchers, according to Thomson Reuter’s Science Watch. Yusuf was a co-author of 13 of the most cited papers in 2011. Only one other researcher, genomic pioneer Eric Lander of the Broad Institute of MIT and Harvard, had more highly-cited papers than Yusuf.
Two of Yusuf’s most-cited papers tested novel anticoagulants in the setting of atrial fibrillation: the RE-LY trial with dabigatran and the AVERROES trial with apixaban.
“It’s a new experience to be called a hottie,” Yusuf joked in an interview with the Hamilton Spectator.“This means it has impact on other scientists. It’s nice to know you’re doing something useful.”
The Science Watch report also included a list of “red-hot” research papers published in 2011. Five of the top 38 papers were cardiology-related:
- S.J. Connolly, et al., “Apixaban in patients with atrial fibrillation,” New Engl. J. Med., 364(9): 806-17, 3 March 2011.
- F. Zannad, et al., “Eplerenone in patients with systolic heart failure and mild symptoms,” New Engl. J. Med., 364(1): 11-21, 6 January 2011.
- H.J. Bouman, et al., “Paraoxonase-1 is a major determinant of clopidogrel efficacy,” Nature Med., 17(1): 110-6, January 2011.
- A.V. Khera, et al., “Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis,” New Engl. J. Med., 364(2): 127-35, 13 January 2011.
- G.W. Stone, et al., “A prospective natural-history study of coronary atherosclerosis,” New Eng. J. Med., 364(3): 226-35, 20 January 2011.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?